BMRN250516C50000
- 9.60
- 0.000.00%
Biomarin Pharmaceutical Newsroom
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $98
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Wedbush Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $94
William Blair Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
BioMarin Pharmaceutical: Hold Rating Amid Promising Trial Results and Safety Concerns
TD Cowen Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $120
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and BioMarin Pharmaceutical (BMRN)
Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $82
Piper Sandler Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $126
Piper Sandler Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BMO Capital Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
Strong Growth Potential and Strategic Positioning Make BioMarin Pharmaceutical a Buy Recommendation
Leerink Partners Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $105
TD Cowen Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $120
BioMarin Pharmaceutical (BMRN) Receives a Buy From TD Cowen
Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $91
Biomarin Pharmaceutical Analyst Ratings
Oppenheimer Upgrades Biomarin Pharmaceutical(BMRN.US) to Buy Rating, Announces Target Price $98
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $80 to $113